CCL

Összesen 14 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM034625
Első szerző:Bonnefoy, Arnaud
Cím:The subendothelium of the HMEC-1 cell line supports thrombus formation in the absence of von Willebrand factor and collagen types I, III and VI / Bonnefoy A., Harsfalvi J., Pfliegler G., Fauvel-Lafeve F., Legrand C.
Dátum:2001
ISSN:0340-6245
Megjegyzések:The macromolecular composition of the extracellular matrix (ECM) produced by the human microvascular endothelial cell line (HMEC-1) was determined by ELISA and its thrombogenicity was studied in blood perfusion assays. Results were compared with those obtained with the ECM produced by human umbilical vein endothelial cells (HUVEC). The HMEC-1's ECM contains collagen type IV, fibronectin, laminin and thrombospondin, but no detectable levels of collagen types I, III and VI, or von Willebrand factor (vWF), whereas all these components were found in the ECM synthesized by HUVEC. HMEC-1's ECM was perfused with low-molecular-weight heparin-anticoagulated blood at two wall shear rates (650/s and 2,600/s), representative of moderate and high arterial wall shear rates, in parallel plate flow chambers for 5 min. This resulted in the formation of large platelet aggregates, compared to essentially a monolayer of adherent platelets on HUVEC's ECM. Interestingly, large thrombi were formed at 2,600/s when HMEC-1's ECM was perfused with the blood of a patient with severe type III von Willebrand disease lacking both plasma and platelet vWF, indicating that vWF was not absolutely required for thrombus formation on this matrix. Thrombin generated on the HMEC-1's ECM contributed importantly to the large platelet thrombi formed, shown by performing blood perfusion experiments in the presence of thrombin inhibitors. Our results indicate that 1) platelet adhesion and aggregate formation on a subendothelium may occur at a high shear rate (2600/s) without the participation of collagen types I, III and VI, and vWF; and 2) the HMEC-1 cell line may prove useful for in vitro studies of the thrombogenic properties of microvascular subendothelium which in most cases does not contain fibrillar collagens and vWF.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Thrombus formation
von Willebrand factor
collagen
HMEC-1
shear rate
extra cellular matrix (ECM)
Megjelenés:Thrombosis And Haemostasis. - 85 : 3 (2001), p. 552-559. -
További szerzők:Hársfalvi Jolán (1949-) (klinikai biokémikus) Pfliegler György (1949-) (belgyógyász, hematológus, labor szakorvos) Fauvel-Lafeve, Francoise Legrand, Chantal
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM010474
Első szerző:Gombos Tímea
Cím:Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure / Gombos, T., Makó, V., Cervenak, L., Papassotiriou, J., Kunde, J., Hársfalvi, J., Förhécz, Z., Pozsonyi, Z., Borgulya, G., Jánoskuti, L., Prohászka, Z.
Dátum:2009
ISSN:0340-6245 (Print)
Megjegyzések:Decreased activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease, was recently reported in cardiovascular diseases and in hepatic failure. Chronic heart failure (CHF) is characterised by abnormalities of left ventricular function accompanied by the failure of the liver and dysregulation of endothelial activation. Therefore, the aim of our study was to measure ADAMTS13 activity in CHF, and determine the prognostic value of VWF and ADAMTS13 on major clinical events in CHF. ADAMTS13 activity (measured by FRETS-VWF73 substrate) was decreased in CHF (n = 152, left ventricular ejection fraction <45%), and it correlated negatively with B-type natriuretic peptide (BNP) NYHA (New York Heart Association) classes, markers of synthetic capacity of the liver and endothelial dysfunction (all p<0.005). Both, high VWF:Ag levels (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.189-1.943), and low ADAMTS13/VWF:Ag ratios (HR 0.70, 95% CI 0.58-0.84) independently and significantly predicted short-term (1 year follow-up) clinical adverse events in heart failure (HF). Decreased activity of ADAMTS13 with concomitant high VWF:Ag levels is a significant independent predictor of clinical events in CHF. The levels of the two molecules may integrate the impaired synthetic capacity of the liver and the disturbed endothelial regulation and can therefore be a useful tool to predict clinical events in CHF.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
ADAMTS13
Endothelial dysfunction
Heart failure
Hepatic failure
Von Willebrand factor
brain natriuretic peptide
von Willebrand factor
von Willebrand factor cleaving proteinase
aged
article
clinical assessment
controlled study
disease association
disease severity
endothelial dysfunction
enzyme activity
female
follow up
heart failure
heart left ventricle ejection fraction
human
liver dysfunction
major clinical study
male
priority journal
prognosis
Megjelenés:Thrombosis and Haemostasis. - 102 : 3 (2009), p. 573-580. -
További szerzők:Makó Veronika Cervenak László Papassotiriou, Jana Kunde, Jan Hársfalvi Jolán (1949-) (klinikai biokémikus) Förhécz Zsolt Pozsonyi Zoltán Borgulya Gábor Jánoskuti Lívia Prohászka Zoltán
Internet cím:elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM044335
Első szerző:Hársfalvi Jolán (klinikai biokémikus)
Cím:Presence and possible origin of epsilon(gamma-glutamyl)lysine isodipeptide in human plasma / J. Harsfalvi, E. Tarcsa, M. Udvardy, G. Zajka, T. Szarvas, L. Fesus
Dátum:1992
ISSN:0340-6245
Megjegyzések:epsilon(gamma-glutamyl)lysine isodipeptide has been detected in normal human plasma by a sensitive HPLC technique in a concentration of 1.9-3.6 mumol/l. Incubation of in vitro clotted plasma at 37 degrees C for 12 h resulted in an increased amount of isodipeptide, and there was no further significant change when streptokinase was also present. Increased in vivo isodipeptide concentrations were also observed in hypercoagulable states and during fibrinolytic therapy.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
lysine isodipeptide
HPLC technique
fibrinolytic therapy
epinephrine
Megjelenés:Thrombosis and Haemostasis. - 67 : 1 (1992), p. 60-62. -
További szerzők:Tarcsa Edit Udvardy Miklós (1947-) (belgyógyász, haematológus) Zajka Gabriella Szarvas T. Fésüs László (1947-) (orvos biokémikus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM033201
Első szerző:Mendelboum Raviv, Shlomit (biológus)
Cím:4-thio-deoxyuridylate modified thrombin aptamer and its inhibitory effect on fibrin clot formation, platelet aggregation and thrombus growrth on subendothelial matrix / S. Mendelboum Raviv, A. Horváth, J. Aradi, Z. Bagoly, F. Fazakas, Z. Batta, L. Muszbek, J. Hársfalvi
Dátum:2008
ISSN:1538-7933
Megjegyzések:Background:?The consensus thrombin aptamer C15-mer is a single-stranded DNA of 15 nucleotides [d(GGTTGGTGTGGTTGG)] that was identified by the selection of thrombin-binding molecules from a large combinatorial library of oligonucleotides. It is capable of inhibiting thrombin at nanomolar concentrations through binding to a specific region within thrombin exosite 1. As has been shown in our earlier studies, the 4-thio-deoxyuridylate (s4dU)-containing oligonucleotides have high affinity for a number of proteins, due to the reduced hydrophilic character of the modified oligonucleotide. Methods:?Three different analogs of the original thrombin-inhibiting sequence, in which some of the thymidylate residues were replaced by 4-thio-deoxyuridylates, were synthesized. The inhibitory effect of modified aptamers was tested on thrombin-catalyzed fibrin clot formation and fibrinopeptide A release from fibrinogen, thrombin-induced platelet aggregation/secretion, and the formation of thrombus on coverslips coated with human collagen type III, thrombin-treated fibrinogen or subendothelial matrix of human microvascular endothelial cells. Results:?As compared with the C15-mer, the analog with the sequence GG(s4dU)TGG(s4dU)G(s4dU)GGT(s4dU)GG (UC15-mer) showed a 2-fold increased inhibition of thrombin-catalyzed fibrin clot formation, fibrinopeptide A release, platelet aggregation and secretion in human plasma and thrombus formation on thrombin-treated fibrinogen surfaces under flow conditions. Concerning the inhibition of thrombin-induced fibrin formation from purified fibrinogen and activation of washed platelets, UC15-mer was 3-fold and twelve-fold more effective than C15-mer, respectively.Conclusion:?The replacement of four thymidylate residues in C15-mer by 4-thio-deoxyuridylate resulted in a new thrombin aptamer with increased anticoagulant and antithrombotic properties.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
4-thio-deoxyuridylate
aptamer
platelets
thrombin
thrombin exosite
thrombus
Megjelenés:Journal Of Thrombosis And Haemostasis. - 6 : 10 (2008), p. 1764-1771. -
További szerzők:Horváth András (1976-) (vegyész) Aradi János (1942-) (biokémikus, vegyész) Bagoly Zsuzsa (1978-) (orvos) Fazakas Ferenc (1969-) (molekuláris biológus) Batta Zoltán Muszbek László (1942-) (haematológus, kutató orvos) Hársfalvi Jolán (1949-) (klinikai biokémikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM010447
Első szerző:Molvarec Attila (szülész-nőgyógyász)
Cím:Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAHTS13) activity in preeclampsia / Molvarec, A., Rigó, J., Jr., Bőze, T., Derzsy, Z., Cervenak, L., Makó, V., Gombos, T., Udvardy, M.L., Hársfalvi, J., Prohászka, Z.
Dátum:2009
ISSN:0340-6245 (Print)
Megjegyzések:The activity of ADAMTS13, the von WiIIebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome. As HELLP syndrome develops in most cases on the basis of preeclampsia, our aim was to determine whether plasma ADAMTS13 activity is decreased in preeclampsia. Sixty-seven preeclamptic patients, 70 healthy pregnant women and 59 healthy non-pregnant women were involved in this case-control study. Plasma ADAMTS13 activity was determined with the FRETS-VWF73 assay, while VWF antigen (VWF:Ag) levels with an enzyme-linked immunosorbent assay. The multimeric pattern of VWF was analyzed by SDS-agarose gel electrophoresis. There was no significant difference in plasma ADAMTS13 activity between the preeclamptic and the healthy pregnant and nonpregnant groups (median [25-75 percentile]: 98.8 [76.5-112.8] %, 96.3 [85.6-116.2] % and 91.6 [78.5-104.4] %, respectively; p>0.05). However, plasma VWF:Ag levels were significantly higher in preeclamptic patients than in healthy pregnant and non-pregnant women (187.1 [145.6-243.1] % versus 129.3 [105.1-182.8] % and 70.0 [60.2-87.3] %, respectively; p<0.001). The multimeric pattern of VWF was normal in each group. Primiparas had lower plasma ADAMTS13 activity than multiparas (92.6 [75.8-110.6] % versus 104.2 [92.1-120.8] %; p=0.011). No other relationship was found between clinical characteristics, laboratory parameters and plasma ADAMTS13 activity in either study group. In conclusion, plasma ADAMTS13 activity is normal in preeclampsia despite the increasedVWF:Ag levels. However, further studies are needed to determine whether a decrease in plasma ADAMTS13 activity could predispose preeclamptic patients to develop HELLP syndrome.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
ADAMTS13
HELLP syndrome
Preeclampsia
Pregnancy
Von Willebrand factor
von Willebrand factor
von Willebrand factor cleaving proteinase
ADAM protein
ADAMTS13 protein
human
biological marker
adult
agar gel electrophoresis
article
case control study
controlled study
enzyme linked immunosorbent assay
female
HELLP syndrome
hemolysis
human
laboratory test
liver
major clinical study
preeclampsia
priority journal
protein blood level
thrombocyte count
blood
enzymology
parity
pregnancy
protein multimerization
upregulation
ADAM Proteins
Adult
Biological Markers
Case-Control Studies
Female
HELLP Syndrome
Humans
Parity
Pre-Eclampsia
Pregnancy
Protein Multimerization
Up-Regulation
von Willebrand Factor
Young Adult
Megjelenés:Thrombosis and Haemostasis. - 101 : 2 (2009), p. 305-311. -
További szerzők:Rigó János (1958-) (szülész-nőgyógyász) Bőze Tamás Derzsy Zoltán Cervenak László Makó Veronika Gombos Tímea Udvardy Miklós László (1977-) (orvos, tudományos segédmunkatárs) Hársfalvi Jolán (1949-) (klinikai biokémikus) Prohászka Zoltán
Internet cím:elektronikus változat
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM073777
Első szerző:Pályu Eszter
Cím:Major changes of von Willebrand factor multimer distribution in cirrhotic patients with stable disease or acute decompensation / Eszter Palyu, Jolan Harsfalvi, Tamas Tornai, Maria Papp, Miklos Udvardy, Katalin Szekeres-Csiki, Lajos Pataki, Karen Vanhoorelbeke, Hendrik B. Feys, Hans Deckmyn, Istvan Tornai
Dátum:2018
ISSN:0340-6245
Megjegyzések:Background and aims: There is an unstable balance between pro- and anti-haemostatic processes in patients with cirrhosis. We hypothesized, that in patients with acute decompensation (AD) the major alterations of von Willebrand factor (VWF) could contribute to the prothrombotic situation as compared to patients with stable (ST) cirrhosis. Methods: We analyzed different parameters of VWF, including detailed multimer distribution by densitometry and platelet adhesion together with ADAMTS13 activity and antigen and C-reactive protein (CRP) levels in patients with ST (n=99), with AD (n=54) and controls (n=92). Results: VWF antigen, ristocetin cofactor as well as collagen binding activities were elevated in both cirrhotic groups in a stepwise manner. There was a decrease in high and an increase in low molecular weight multimer ratios in the majority of ST cirrhosis. However, in 24 out of 54 AD patients ultra-large VWF multimers (ULMWM) were found. ADAMTS13 activity in ST and AD patients without ULMWM was similar to controls [median, (IQR)%: 98 (67-132) and 91 (60-110) vs. 106 (88-117), respectively]. The presence of ULMWM in AD patients was associated with low ADAMTS13 activity [33 (24-49)%] and high CRP level [23 (7.1-83.6)mg/l]. Adhesion of normal platelets showed a stepwise increase in the presence of cirrhotic plasmas, reaching the highest level in AD patients with ULMWM. Conclusion: Characteristic changes of VWF parameters are seen in ST cirrhosis. In AD patients highly increased VWF and reduced ADAMTS13 activity could be found, along with the presence of ULMWM, which are possible markers and contributors of the disease progression.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
cirrhosis
acute decompensation
systemic inflammation
von Willebrand factor multimers
trhombotic microangiopathy
Megjelenés:Thrombosis and Haemostasis. - 118 : 8 (2018), p. 1397-1408. -
További szerzők:Hársfalvi Jolán (1949-) (klinikai biokémikus) Tornai Tamás István (1984-) (belgyógyász) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Udvardy Miklós (1947-) (belgyógyász, haematológus) Szekeres-Csiki Katalin (1979-) (orvos) Pataki Lajos Vanhoorelbeke, Karen Feys, Hendrik B. Deckmyn, Hans Tornai István (1954-) (belgyógyász, gasztroenterológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM071315
Első szerző:Selmeczi Anna (orvos)
Cím:Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia / Selmeczi Anna, Rachel E. J. Roach, Móré Csaba, Batta Zoltán, Hársfalvi Jolán, Anske Van de Bom, Boda Zoltán, Oláh Zsolt
Dátum:2015
ISSN:0340-6245
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Thrombosis and Haemostasis 113 : 2 (2015), p. 283-289. -
További szerzők:Roach, Rachel E. J. Móré Csaba (1971-) (szülész-nőgyógyász) Batta Zoltán Hársfalvi Jolán (1949-) (klinikai biokémikus) Van de Bom, Anske Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Oláh Zsolt (1974-) (belgyógyász)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM010452
Első szerző:Szántó Tímea
Cím:Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction / Szanto, T., Vanhoorelbeke, K., Toth, G., Vandenbulcke, A., Toth, J., Noppe, W., Deckmyn, H., Harsfalvi, J.
Dátum:2009
ISSN:1538-7933 (Print)
Megjegyzések:Because the collagen-VWF-GPIb/IX/V axis plays an important role in thrombus formation, it represents a promising target for development of new antithrombotic agents. Objectives: We used phage display to identify potential small peptides that interfere with the VWF-collagen binding and might serve as lead products for the development of possible oral antithrombotic compounds. Methods: A random linear heptamer peptide library was used to select VWF-binding peptides. Results: We identified a phage clone, displaying the YDPWTPS sequence, further referred to as L7-phage, that bound to VWF in a specific and a dose-dependent manner. This L7-phage specifically inhibited the VWF-collagen interaction under both static and flow conditions. Epitope mapping using deletion mutants of VWF revealed that the L7-phage does not bind to the known collagen-binding A3 domain within VWF, but to the more carboxyterminal situated C domain. This inhibition was not due to steric hindrance of the A3 domain-collagen interaction by the L7-phage. Indeed, a tetrabranched multi-antigen peptide (MAP) presenting four copies of the peptide, but not the scrambled MAP, also inhibited VWF-collagen interaction under conditions of high shear stress at a concentration of 148 nmol L<sup>-1</sup>. Conclusions: Based on these results, we conclude that we have identified the first peptide antagonist that binds to the VWF C domain and by this specifically inhibits the VWF binding to collagen, suppressing platelet adhesion and aggregation under high shear conditions. As a consequence, this peptide and its future derivates are potentially interesting antithrombotic agents.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Antithrombotic therapy
Collagen
Peptide inhibitor
Phage display
Platelet adhesion
Von Willebrand factor
antithrombocytic agent
collagen
epitope
unclassified drug
von Willebrand factor
amino acid sequence
article
biopanning
carboxy terminal sequence
concentration response
controlled study
deletion mutant
drug mechanism
drug protein binding
drug screening
human
normal human
phage display
priority journal
protein binding
protein domain
protein protein interaction
shear stress
stereospecificity
thrombocyte adhesion
thrombocyte aggregation inhibition
Collagen
Dose-Response Relationship
Drug
Drug Design
Drug Evaluation
Preclinical
Epitope Mapping
Fibrinolytic Agents
Hemorheology
Humans
Oligopeptides
Peptide Library
Platelet Adhesiveness
Platelet Aggregation
Platelet Aggregation Inhibitors
Protein Binding
Stress
Mechanical
von Willebrand Factor
Megjelenés:Journal of Thrombosis and Haemostasis. - 7 : 10 (2009), p. 1680-1687. -
További szerzők:Vanhoorelbeke, Karen Tóth Gábor (Szeged) Vandenbulcke, A. Tóth Judit (1978-) (laboratóriumi szakorvos) Noppe, W. Deckmyn, Hans Hársfalvi Jolán (1949-) (klinikai biokémikus)
Internet cím:elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

9.

001-es BibID:BIBFORM002138
Első szerző:Szántó Tímea
Cím:The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha / Szanto T., Schlammadinger A., Staelens S., De Meyer S. F., Freson K., Pareyn I., Vauterin S., Harsfalvi J., Deckmyn H., Vanhoorelbeke K.
Dátum:2007
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Thrombosis Haemostasis. - 98 : 1 (2007), p. 178-185. -
További szerzők:Schlammadinger Ágota (1971-) (belgyógyász, haematológus) Staelens, Stephanie De Meyer, Simon F. Freson, Kathleen Pareyn, Inge Vauterin, Stephan Deckmyn, Hans Vanhoorelbeke, Karen Hársfalvi Jolán (1949-) (klinikai biokémikus)
Internet cím:elektronikus változat
DOI
Borító:

10.

001-es BibID:BIBFORM002137
Első szerző:Szántó Tímea
Cím:Type 2B von Willebrand disease in seven individuals from three different families : phenotypic and genotypic characterization / Szanto T., Schlammadinger A., Salles I., Pareyn I., Vauterin S., Harsfalvi J., Vanden Bulcke A. M., Deckmyn H., Vanhoorelbeke K.
Dátum:2007
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Thrombosis Haemostasis. - 98 : 1 (2007), p. 251-254. -
További szerzők:Schlammadinger Ágota (1971-) (belgyógyász, haematológus) Salles, Isabelle Pareyn, Inge Vauterin, Stephan Vanden Bulcke, Anne-Marie Deckmyn, Hans Vanhoorelbeke, Karen Hársfalvi Jolán (1949-) (klinikai biokémikus)
Internet cím:elektronikus változat
DOI
Borító:

11.

001-es BibID:BIBFORM010455
Első szerző:Udvardy Miklós László (orvos, tudományos segédmunkatárs)
Cím:Novel evaluation method for densitometric curves of von Willebrand factor multimers and a new parameter (MMW) to describe the degree of multimersation / Udvardy, M. L., Szekeres-Csiki, K., Hársfalvi, J.
Dátum:2009
ISSN:0340-6245 (Print)
Megjegyzések:Von Willebrand factor (VWF) is built up from a varying number of subunits, of which the larger molecules have higher haemostatic activity. Von Willebrand disease (VWD) and thrombotic thrombocytopenic purpura are the best known disorders with pathognomonic changes of the highly multimerised VWF forms. There is an established method to calculate the relative amount of large oligomers. Our aim is to quantify the degree of VWF multimerisation as well, to complete the densitometric analysis of VWF electrophoresis. After optimisation, we have defined this new parameter (MMW) as the molecular weight corresponding to the lower boundary of the largest 25% of VWF protein. MMW was significantly different (p&amp;lt;.0001) in platelet lysate, normal samples and VWD type 2 samples (10.4, 6.3, 2.1, respectively). There was strong correlation between the MMW and the amount of large multimers in normal samples (r2=0.98) and in platelet lysate. However MMW was higher in platelet lysate, in which VWF is not cleaved by ADAMTS-13, than in healthy samples with the same amount of large multimers. Comparison of the new parameter and the collagen binding and ristocetin cofactor activity of VWF, showed that the functional tests are at least partially determined by the multimerisation; however, about 15% of VWD samples had normal activity to antigen ratios. The quantification of multimerisation aids the classification in these cases, especially at low antigen concentrations, and also might help in the detection of thrombotic conditions.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Von Willebrand disease
VWF multimer analysis
collagen
oligomer
ristocetin
von Willebrand factor
von Willebrand factor cleaving proteinase
ADAM protein
ADAMTS13 protein
human
buffer
multiprotein complex
analytic method
article
cell lysate
controlled study
densitometry
function test
hemostasis
human
human cell
molecular weight
polyacrylamide gel electrophoresis
priority journal
quantitative analysis
thrombotic thrombocytopenic purpura
von Willebrand disease
blood
case control study
chemistry
comparative study
evaluation
in vitro study
metabolism
methodology
protein binding
protein quaternary structure
statistics
ADAM Proteins
Buffers
Case-Control Studies
Collagen
Densitometry
Humans
Molecular Weight
Multiprotein Complexes
Protein Binding
Protein Structure
Quaternary
von Willebrand Disease
von Willebrand Factor
Megjelenés:Thrombosis and Haemostasis. - 102 : 2 (2009), p. 412-417. -
További szerzők:Szekeres-Csiki Katalin (1979-) (orvos) Hársfalvi Jolán (1949-) (klinikai biokémikus)
Internet cím:elektronikus változat
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

12.

001-es BibID:BIBFORM036487
Első szerző:Udvardy Miklós (belgyógyász, haematológus)
Cím:Thrombotic changes in haemostasis following intravenous streptokinase treatment for acute myocardial infarction / Miklós Udvardy, Jolán Hársfalvi, Zoltán Boda, Kálmán Rák
Dátum:1990
ISSN:0340-6245
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Thrombosis And Haemostasis. - 63 : 1 (1990), p. 146-147. -
További szerzők:Hársfalvi Jolán (1949-) (klinikai biokémikus) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Rák Kálmán (1929-2005) (belgyógyász, klinikai hematológus, véralvadás kutató)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.